Opportunities for Collaboration
WRA has filed patents describing the development of unique antibodies that bind to calcitonin receptor expressed in leukaemia, cardiovascular disease, wound healing, brain tumours and as a novel event in apoptosis.
WRA recognises the strategic importance of strong collaboration to develop and promote viable projects.
An early strategic focus of WRA included the development of useful antibodies that target key cells in diseased or damaged tissue.
WRA seeks collaboration to promote translational research and clinical trials using IP established by WRA.